Jaime is a freelance writer for The American Journal of Managed Care® (AJMC®), where she previously worked as an assistant editor.
She has a BA in print journalism from Penn State University. You can connect with Jaime on LinkedIn.
Is a New Classification and Prognosis System Possible for Myelodysplastic Syndromes?
January 2nd 2021Integrating novel parameters into conventional risk stratification systems may better define patient subgroups in myelodysplastic syndromes (MDS), thus creating a more enhanced classification and prognostic scoring system for patients, say researchers.
Read More
Unanswered Questions Remain in Optimal Management of RBC Transfusions in MDS
January 1st 2021Questions remain about the optimal approach to transfusion management in myelodysplastic syndromes (MDS), particularly in the outpatient setting, leading a pair of researchers to review current evidence.
Read More
What a Review Says About Biologics for Allergic Bronchopulmonary Aspergillosis, Asthma, CF
December 27th 2020The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).
Read More
Immunosuppressive Drugs for Autoimmune Disease May Reduce Risk of ARDS in COVID-19 Hospitalizations
December 27th 2020Immunosuppressed patients who had an autoimmune disease (AD) were significantly less likely to develop severe acute respiratory distress syndrome (ARDS) compared with patients who were not immunosuppressed and did not have an AD.
Read More
Secukinumab Improves Signs, Symptoms of Axial Disease in Patients With PsA
December 24th 2020Both secukinumab 300 mg and secukinumab 150 mg significantly improved signs and symptoms of axial disease in patients with psoriatic arthritis (PsA) who had inadequate response to non- steroidal anti-inflammatory drugs.
Read More
Heterogenous Nature of MDS Warrants Further Research, Review Finds
December 23rd 2020With a goal of moving toward more individualized therapeutic approaches, researchers said future advancements in understanding myelodysplastic syndrome (MDS) molecular mechanisms are needed to offer clinical decision making guidance.
Read More
Gene Expression Signatures Linked With Response to HMA Treatment in Patients With MDS
December 19th 2020Their work may help to further understanding of the molecular mechanisms of hypomethylating agents (HMAs) and offer a guide for determining which patients are likely to respond to such treatment.
Read More
For Patients With HMA-Resistant MDS, What Are Their Options?
December 18th 2020For patients who are resistant to hypomethylating agent (HMA) treatment, there are no formal treatment recommendations, but several options, spanning from novel HMAs to chemotherapy, have been or are currently being studied in the setting.
Read More
Study Finds Significant Survival Advantage for Patients With MDS Who Have HLA-Matched Donor for HCT
December 12th 2020The abstract, presented at the 2020 American Society of Hematology Annual Meeting and Exposition, found favorable overall survival and leukemia-free survival for these patients.
Read More
Dr Hope Rugo on the Importance of a Potential Oral Paclitaxel Option in Metastatic Breast Cancer
December 11th 2020Hope Rugo, MD, director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the benefits of oral paclitaxel in metastatic breast cancer.
Read More
Studies Highlight Multiple Underlying Etiologies of PAH, Predictive Factors of PAA
December 10th 2020A group of researchers published their research on the various underlying etiologies of pulmonary arterial hypertension (PAH), as well as predictive factors of pulmonary artery aneurysms (PAAs).
Read More
Despite Favorable Safety, Olesoxime Falls Short Among Efficacy Markers for SMA
December 10th 2020Long-term follow-up of the treatment showed that while it has a favorable safety profile, the treatment does not offer significant efficacy for patients with spinal muscular atrophy (SMA) type 2 and non-ambulant type 3.
Read More
A Look at Established, Emerging Biomarkers for I-O Therapy in Breast Cancer
December 10th 2020During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.
Read More
Population Carrier Screening Increases Prenatal SMA Diagnoses, Reduces SMA Births
December 7th 2020Between the first introduction of population carrier screening in 2008 and its expansion to the full Israeli population in 2013, the mean rate of prenatal diagnoses per year was 4.66, and this rose to 7.75 between 2014 and 2017, a 66% increase.
Read More
A Look at the Use of Echocardiography to Assess Macitentan Effects, Predict Mortality in PAH
December 5th 2020Two studies presented at CHEST 2020 assessed the impact of macitentan on cardiac function in pulmonary arterial hypertension (PAH) and determined what role reproducible exercise echocardiographic parameters have in predicting survival.
Read More